IPSC

Century Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.61
52-Week Range: $0.44 – $3.04
Market Cap: $277.05M
P/E (TTM): —
EPS (TTM): -0.93
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.19
PEG Ratio: —
Return on Equity: -49.65%
Return on Assets: -23.51%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 8.28
Debt/Equity: 0.17
Total Debt: $38.67M
Free Cash Flow: $-50.41M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $196.00M

IPSC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$5.20M	$2.23M	$6.59M	$109.16M
Research & Development	$97.17M	$92.71M	$107.24M	$95.67M
Selling, General & Admin	$31.86M	$34.71M	$33.16M	$24.00M
Operating Expenses	$129.03M	$127.42M	$140.40M	$119.67M
Operating Income	-$123.83M	-$125.18M	-$133.81M	-$10.51M
EBITDA	-$121.20M	-$121.21M	-$120.51M	$2.60M
Pretax Income	-$130.84M	-$134.79M	-$124.78M	-$9.65M
Income Tax	$91.00K	$1.88M	$1.79M	-$68.00K
Net Income	-$130.93M	-$136.67M	-$126.57M	-$9.58M
Diluted EPS	-2.27	-2.30	-1.61	-0.14
Diluted Shares	57.76M	59.31M	78.65M	86.56M

IPSC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$84.27M	$47.32M	$58.44M	$61.85M
Receivables	$780.00K	$2.23M	$1.52M	$667.00K
Current Assets	$319.72M	$176.99M	$194.05M	$120.77M
Total Assets	$486.54M	$360.69M	$353.22M	$223.70M
Current Liabilities	$29.82M	$17.85M	$129.78M	$20.23M
Long-Term Debt	$3.74M	—	—	—
Total Debt	$49.41M	$48.17M	$53.83M	$43.56M
Total Liabilities	$183.81M	$175.94M	$191.85M	$64.77M
Retained Earnings	-$519.10M	-$655.77M	-$782.34M	-$791.92M
Shareholders' Equity	$302.74M	$184.75M	$161.36M	$158.94M
Working Capital	$289.90M	$159.15M	$64.27M	$100.54M

IPSC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$14.05M	-$88.35M	-$110.14M	-$103.88M
Capital Expenditure	-$30.60M	-$13.74M	-$154.00K	-$848.00K
Free Cash Flow	-$16.55M	-$102.08M	-$110.29M	-$104.72M
Depreciation & Amortisation	$8.44M	$13.04M	$13.30M	$13.10M
Stock-Based Compensation	$10.67M	$14.62M	$12.69M	$6.84M
Investing Cash Flow	-$13.13M	$61.13M	$47.48M	$107.50M
Financing Cash Flow	$27.16M	-$9.72M	$74.56M	$173.00K
Net Change in Cash	$28.08M	-$36.94M	$11.91M	$3.80M

IPSC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$109.16M	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$26.58M	$26.86M	$22.53M	$19.70M	$17.11M	$19.59M
Selling, General & Admin	$8.41M	$7.80M	$6.83M	$956.00K	$6.58M	$5.79M
Operating Expenses	$34.99M	$34.66M	$29.36M	$20.65M	$23.68M	$25.38M
Operating Income	$74.18M	-$34.66M	-$29.36M	-$20.65M	-$23.68M	-$25.38M
EBITDA	$77.40M	-$31.46M	-$26.23M	-$17.10M	-$20.68M	-$22.77M
Pretax Income	$76.56M	-$32.54M	-$34.42M	-$19.24M	-$21.64M	-$34.55M
Income Tax	$0.00	$0.00	$0.00	-$68.00K	—	—
Net Income	$76.56M	-$32.54M	-$34.42M	-$19.17M	-$21.64M	-$34.55M
Diluted EPS	0.89	-0.38	-0.40	—	-0.11	-0.17
Diluted Shares	86.10M	86.24M	86.46M	—	193.47M	205.78M

IPSC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$51.87M	$56.88M	$55.52M	$61.85M	$51.05M	$49.64M
Receivables	—	—	—	$667.00K	—	—
Current Assets	$169.63M	$160.17M	$137.71M	$120.77M	$139.04M	$124.77M
Total Assets	$315.61M	$284.69M	$244.72M	$223.70M	$326.55M	$287.01M
Current Liabilities	$14.50M	$14.95M	$22.03M	$20.23M	$13.57M	$15.07M
Total Debt	$52.67M	$51.48M	$44.96M	$43.56M	$48.02M	$38.67M
Total Liabilities	$75.17M	$74.79M	$68.37M	$64.77M	$61.81M	$54.66M
Retained Earnings	-$705.78M	-$738.32M	-$772.74M	-$791.92M	-$813.56M	-$848.11M
Shareholders' Equity	$240.44M	$209.90M	$176.35M	$158.94M	$264.74M	$232.34M
Working Capital	$155.13M	$145.22M	$115.68M	$100.54M	$125.47M	$109.70M

IPSC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$34.62M	-$27.59M	-$25.58M	-$16.08M	-$25.26M	-$19.83M
Capital Expenditure	-$475.00K	-$317.00K	-$195.00K	—	-$584.00K	-$694.00K
Free Cash Flow	-$35.10M	-$27.91M	-$25.78M	-$15.94M	-$25.85M	-$20.53M
Depreciation & Amortisation	$3.22M	$3.20M	$3.13M	$3.55M	$3.00M	$2.62M
Stock-Based Compensation	$2.43M	$2.22M	$892.00K	$1.30M	$1.45M	$1.95M
Investing Cash Flow	$27.93M	$32.54M	$24.67M	$22.36M	-$112.61M	$17.77M
Financing Cash Flow	$120.00K	$0.00	$0.00	$53.00K	$126.62M	$311.00K
Net Change in Cash	-$6.57M	$4.95M	-$913.00K	$6.34M	-$11.25M	-$1.76M

Market Snapshot

About

Century Therapeutics is a biotechnology company developing innovative cell therapies for cancer treatment. The company engineers induced pluripotent stem cells (iPSCs) to create allogeneic CAR-T and CAR-NK cell therapies that can be manufactured at scale. Century's platform aims to overcome limitations of autologous cell therapies by providing off-the-shelf treatments with improved persistence and functionality. The company is advancing multiple programs through clinical development targeting hematologic malignancies and solid tumors.